Intezyne is a clinical-stage company with an extensive portfolio of product candidates that may offer physicians and patients significant advances in treating a wide variety of tumors.

Latest News

 

Spotlight

IT-235
Intezyne’s IT-235 is a first-in-class targeted gallium-based small molecule administered as oral tablets once daily.

 

IVECT™ Method

Intezyne, Inc. believes the IVECT Method is a unique and remarkably safe platform that has the potential to raise the bar in terms of what patients and oncologists can expect from chemotherapy.